- Home
- AIIO vs LSTA Comparison
AIIO vs LSTA Comparison
Compare AIIO & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AIIO | LSTA |
|---|---|---|
| Founded | N/A | 1980 |
| Country | United Arab Emirates | United States |
| Employees | 68 | N/A |
| Industry | Auto Manufacturing | Misc Health and Biotechnology Services |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.5M | 28.9M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | AIIO | LSTA |
|---|---|---|
| Price | $3.14 | $3.47 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 3.0M | 105.0K |
| Earning Date | 05-27-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.42 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,283,868.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 56.90 |
| 52 Week Low | $0.07 | $1.81 |
| 52 Week High | $9.20 | $5.07 |
Technical Indicators
Market Signals| Indicator | AIIO | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 56.13 | 51.45 |
| Support Level | $0.34 | $3.06 |
| Resistance Level | $9.20 | $3.67 |
| Average True Range (ATR) | 0.37 | 0.14 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 66.61 | 24.32 |
Price Performance
Historical ComparisonAbout AIIO Robo.ai Inc. Class B Ordinary Shares
Robo.ai Inc is a pioneering smart electric vehicle company which aims to integrate avant-garde design, life-style personalization, IoT connectivity, and autonomous driving technology into a passenger-centric green premium mobility solution to the world. Geographically, the company operates in The United States, The United Arab Emirates, Mainland China.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.